Molecular Sensing Leadership Team
STAFF
Dr. Rich has over 30 years experience in research, marketing, and general management in the instrumentation field. He is a founder, and retired CEO/President of Ciphergen Biosystems. He was CEO/President of BioSepra, SVP of Sepracor, and SVP of Dionex, as a member of the founding team. Dr. Rich received his PhD in chemistry from the University of North Carolina, Chapel Hill and completed post-doctoral work at Duke University in biochemistry. He completed the Executive Management Program at Stanford University. He holds a number of patents related to bioanalytical instrumentation.
Scot has over 20 years experience in life science instrumentation before founding Molecular Sensing. Most recently, he founded GenNext Technologies, a company dedicated to advancing education in translational medicine. Scot was Director of Research Proteomics for Ciphergen Biosystems, where he led R&D in mass spectrometry and molecular interaction technology. Earlier in his career he was VP of R&D at Linear Scientific, which he helped sell to Hewlett-Packard and Spectra-Physics and subsequently held key R&D positions at both companies. Scot’s academic training was in cellular biology with a BS degree and post-graduate medical school training from the University of Nevada, Reno. Scot holds 30 different US and international patents in the areas of life science research.
Wilt Peters has more than 40 years of experience in sales, marketing and general management in the analytical instrumentation field. Wilt was General Manager of Dionex GmbH and most recently served as European General Manager for Caliper Life Sciences. Before that, Wilt served as European General Manager for Caliper Technologies and General Manager for Caliper Life Sciences GmbH. He studied analytical chemistry at the University of Applied Sciences Fresenius.BOARD OF DIRECTORS & INVESTORS
Dr. Laden co-founded TriStar Technology Ventures in 2009. Through his role at TriStar, he serves on the Board of Directors for VenX, Molecular Sensing, GOBA and Diagnovus. Prior to the founding of TriStar, Dr. Laden served as the Assistant Director in the Office of Technology Transfer and Enterprise Development at Vanderbilt University. That role involved leading various technology transfer functions for Vanderbilt, which included identifying, protecting, marketing and licensing promising new technologies to companies of all stages and sizes, as well as developing collaborative, sponsored R&D and material transfer relationships with industry. He also participated in the office’s venture investment and company formation activities. Since beginning as the Chancellor Fund in 2000, Vanderbilt invested a substantial amount of capital into 30 different Vanderbilt-related companies. Before moving into technology transfer, Dr. Laden was a postdoctoral researcher in the Department of Biochemistry at Vanderbilt, where his work focused on structure-function studies of the cytochromes P450. He holds a doctorate in Toxicology from the University of Kentucky, a master’s degree in Environmental and Industrial Health from the University of Michigan and an undergraduate degree in biology from Penn State University.
Mr. Rand co-founded TriStar Technology Ventures in 2009. Through his role at TriStar, he serves on the Board of Directors for Pathfinder Therapeutics, MedCenterDisplay, Molecular Sensing, Nashville Technology Council, Nashville Entrepreneur Center, Nashville Capital Network, E|Spaces and Bridge Nashville. Prior to co-founding TriStar, Mr. Rand was the Manager of New Venture Development in Vanderbilt’s Office of Technology Transfer and Enterprise Development. That responsibility included licensing Vanderbilt intellectual property, assisting in the formation of new start-up companies and working with existing start-ups. Since beginning as the Chancellor’s Fund in 2000, Vanderbilt has invested a significant amount of capital into 30 different Vanderbilt-related companies. Mr. Rand was responsible for managing this portfolio and represented Vanderbilt on the boards of five of these companies. Prior to joining Vanderbilt, Mr. Rand worked in PricewaterhouseCoopers’ valuation group, providing consulting and transaction support services. He received his undergraduate degree from the University of Notre Dame and his MBA from Vanderbilt.
Dr. Rick L. Ryan serves as the Chief Executive Officer of Apertus Pharmaceuticals where he provides strategic direction to the company and its partnerships with pharmaceutical companies, venture capital firms, universities and research institutions. Rick has over 30 years experience in the life sciences industry including business management and new business/technology development. He has held executive leadership positions in multinational corporations as well as early stage ventures. Before joining Apertus, Rick was Vice President of the Drug Discovery & Development business unit at Millipore Corporation. He had P&L responsibility for DDD, which provided discovery and development products and services to Pharma and Biotech customers. At Millipore he also led innovation programs, such as biomarker applications for discovery, and development for companion diagnostic applications. Rick was formerly the President of LINCO Research Inc, which was acquired by Millipore in 2007. He started his biotechnology career at Monsanto, where he held several technology and business management positions of increasing responsibility, including Dir. Commercial/Business Development, Dir. Strategic Planning and Dir. International Markets. Rick received his PhD (Biochemistry) from the University of Illinois and his executive MBA from Washington University in St. Louis. He was an American Cancer Society post-doctoral fellow at the University of Wisconsin. He obtained his B.S. in chemistry from Central College of Iowa.
Dr. Rich has over 30 years experience in research, marketing, and general management in the instrumentation field. He is a founder, and retired CEO/President of Ciphergen Biosystems. He was CEO/President of BioSepra, SVP of Sepracor, and SVP of Dionex, as a member of the founding team. Dr. Rich received his PhD in chemistry from the University of North Carolina, Chapel Hill and completed post-doctoral work at Duke University in biochemistry. He completed the Executive Management Program at Stanford University. He holds a number of patents related to bioanalytical instrumentation.Scot has over 20 years experience in life science instrumentation before founding Molecular Sensing. Most recently, he founded GenNext Technologies, a company dedicated to advancing education in translational medicine. Scot was Director of Research Proteomics for Ciphergen Biosystems, where he led R&D in mass spectrometry and molecular interaction technology. Earlier in his career he was VP of R&D at Linear Scientific, which he helped sell to Hewlett-Packard and Spectra-Physics and subsequently held key R&D positions at both companies. Scot’s academic training was in cellular biology with a BS degree and post-graduate medical school training from the University of Nevada, Reno. Scot holds 30 different US and international patents in the areas of life science research.SCIENTIFIC ADVISORS
Dr. Walter Huber is a well-known expert in the field of biosensors and spectroscopy. After joining Hoffmann-La Roche in 1987 as Project Leader for the development of optical biosensors based on waveguide technologies, he became Section Head Optical Spectroscopy in 1996. In 2011 he was awarded the position of Distinguished Scientist responsible for label-free applications, specifically SPR. Walter Huber received his PhD in physical chemistry at the University of Basel where he also lectures as Privatdozent. He retired from Roche at the end of 2014.